Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Facebook, McDonald's, Bristol-Myers Squibb, Netflix, and U.S. Bancorp

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 14, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Facebook, Inc. (FB - Free Report) , McDonald's Corporation (MCD - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) , Netflix, Inc. (NFLX - Free Report) and U.S. Bancorp (USB - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Facebook, McDonalds and Bristol Myers

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Facebook, McDonalds and Bristol-Myers Squibb. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Facebook shares have outperformed the S&P 500 in the year-to-date period (+30.6% vs. +3.8%) on the back of steady user growth across all regions, particularly the Asia Pacific region.

The coronavirus-led lockdowns and shelter-at-place guidelines have increased engagement of its products like Instagram, WhatsApp, Messenger and Facebook Watch. However, Facebook expects user-base growth to be flat or slightly down in most of its regions in the third quarter of 2020, sequentially. The company expects ad-revenue growth on a year-over-year basis to be roughly 10%.

Facebook assumes some of the recent surge in community engagement to normalize as regions reopen. Further, a number of companies have announced plans to freeze ad spending on Facebook due to its failure to eradicate hate speech and misinformation. This is expected to hurt top-line growth, at least in the near term.

(You can read the full research report on Facebook here >>>)

Shares of McDonalds have gained +27.7% over the past six months against the Zacks Restaurants industry’s rise of +35.4%. The Zacks analyst believes that the company is benefiting from an increase in drive-thru sales.

McDonald’s increased focus on delivery and accelerated deployment of EOTF restaurants in the United States is commendable. Additionally, the company is making every effort to drive growth in international markets as well. Of late, earning estimates for 2020 have increased.

The company witnessed continued improvement in results throughout the second quarter. However, dismal comps and high debt is hurting the company. The company’s comps declined for the second straight quarter after reporting positive comps in the preceding 19 quarters. Moreover, the company is witnessing dismal traffic due to the pandemic.

(You can read the full research report on McDonalds here >>>)

Bristol-Myers shares have gained +17.5% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +9.3%. The Zacks analyst believes that Bristol-Myers’ blockbuster immuno-oncology drug, Opdivo, and blood thinner drug, Eliquis, will drive growth for the company.

Eliquis is the leading oral anti-coagulant drug and the company continues to witness growth in both Eliquis brand and the market. The label expansion of Opdivo for first-line NSCLC should boost prospects. The addition of sales from Celgene’s drugs (acquired in November 2019) has boosted growth prospects. In particular, the addition of Revlimid has strengthened the oncology portfolio.

The company lifted its earnings guidance for 2020 in hope of a possible recovery in the second half of 2020. Shares have outperformed the industry in the past year. However, Opdivo’s performance was dismal as it faces stiff competition from Keytruda and Tecentriq. Moreover, concerns will rise once Revlimid loses patent protection.

(You can read the full research report on Bristol-Myers here >>>)

Other noteworthy reports we are featuring today include Netflix and U.S. Bancorp.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                                 


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in